My Mahoney (Thomas Jefferson University) discussed the role of the cadherin and cancer biomarker desmoglein 2 (Dsg2) in head and neck squamous cell carcinoma (HNSCC), especially in the context of therapy with immune checkpoint inhibitors (ICI). This evidence concerns the gene DSG2 and head and neck squamous cell carcinoma.